Heard on the Street Recap: Cease-Fire
What Happened in Markets Today
A shaky cease-fire between Israel and Iran sent a burst of optimism through markets. Investors had been looking warily at the possibility of a widening conflict in the Middle East after the U.S. struck Iranian nuclear sites over the weekend. But Iran's mild response to the U.S. attack and its truce with Israel, however fragile, tempered those concerns.
Stocks rallied. The S&P 500 rose 1.1%, the Nasdaq gained 1.4% and the Dow Jones Industrial Average added 507 points.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
Forte Biosciences Announces Pricing of $75 Million Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up to 619,606 shares of common stock at a price to the public of $11.999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.001 per share exercise price for each pre-funded warrant. In addition, Forte has granted the underwriters a 30-day option to purchase up to an additional 937,508 shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock and pre-funded warrants are being offered by Forte. The gross proceeds from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about June 26, 2025, subject to satisfaction of customary closing conditions. Forte intends to use the net proceeds of the offering for working capital and other general corporate purposes, which includes funding clinical and preclinical development of its product candidate and other research activities. TD Cowen, Evercore ISI, Guggenheim Securities and Chardan are acting as joint book-running managers for the offering. Lucid Capital Markets and Brookline Capital Markets, a division of Arcadia Securities, LLC are acting as co-managers for the offering. The offering is being made pursuant to a Registration Statement on Form S-3 (File No. 333-286226), including a base prospectus, previously filed with and declared effective by the SEC. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC. A final prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed for free through the SEC's website at Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (855) 495-9846 or by email at Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888)-474-0200, or by email at Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ and Chardan Capital Markets, LLC, One Pennsylvania Plaza, Suite 4800, New York, NY 10119. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Forte Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. Forward Looking Statements Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential' or 'continue' or the negatives of these terms or other similar expressions. These statements are based on the Forte's current beliefs and expectations. Forward-looking statements include statements regarding the completion and timing of the offering and the anticipated use of proceeds from the offering. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: whether or not Forte will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Additional risks, uncertainties, and other information affecting Forte's business and operating results are contained in Forte's Quarterly Report on Form 10-Q filed on May 15, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Source: Forte Biosciences, Inc.
Business Wire
31 minutes ago
- Business Wire
Faraday X Announces FX Super One Private Preview & Co-Creation Event Set for June 29, With Multiple Super One Vehicles Ready to Welcome Over 100 Invited Guests
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ('Faraday Future', 'FF' or 'Company'), a California-based global shared intelligent electric mobility ecosystem company, announced that final preparations are underway for the exclusive private preview and Co-Creation launch event for its new groundbreaking FX Super One MPV on Sunday, June 29, in Los Angeles, with several FX Super One vehicles set to be unveiled at the event. The FX Super One, FX's first planned model, which would be the first-ever First Class AI-MPV designed for the U.S. market, will be unveiled at this invite-only event. The Company has confirmed attendance from over 100 distinguished guests that include FF stockholders and investors, B2B sales partners and prospects, global supply chain partners, media, key opinion leaders (KOLs) and influencers, and Co-Creation officers. With less than a week to go, the entire FF and FX teams are in the final stretch. Preparations include vehicle calibration, on-site setup, confirmation of guest logistics, and coordination of test rides and drive experiences. The overwhelming interest and response from potential attendees reflect the anticipation surrounding this new species of mobility and innovation. This event marks the beginning of Faraday X's 'Product Execution & Launch Season.' The company will follow up with a First Online Global Product Launch of the FX Super One on July 17, 2025, open to audiences worldwide. ABOUT FARADAY FUTURE Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company's mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future's flagship model, the FF91, exemplifies its vision for luxury, innovation, and performance. The FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. FF is committed to redefining mobility through AI innovation. Join us in shaping the future of intelligent transportation. For more information, please visit FORWARD LOOKING STATEMENTS This press release includes 'forward looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'will,' 'should,' 'to,' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding the Super One MPV, are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, among others: the Company's ability to secure necessary agreements to license or produce FX vehicles in the U.S., the Middle East, or elsewhere, none of which have been secured; the Company's ability to homologate FX vehicles for sale in the U.S., the Middle East, or elsewhere; and the Company's ability to secure necessary permits at its Hanford, CA production facility; the potential impact of tariff policy; the Company's ability to continue as a going concern and improve its liquidity and financial position; the Company's ability to pay its outstanding obligations; the Company's ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company's limited operating history and the significant barriers to growth it faces; the Company's history of losses and expectation of continued losses; the success of the Company's payroll expense reduction plan; the Company's ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company's estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company's vehicles; the Company's ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company's vehicles; current and potential litigation involving the Company; the Company's ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company's indebtedness; the Company's ability to cover future warranty claims; the Company's ability to use its 'at-the-market' program; insurance coverage; general economic and market conditions impacting demand for the Company's products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company's control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company's operations in China; the success of the Company's remedial measures taken in response to the Special Committee findings; the Company's dependence on its suppliers and contract manufacturer; the Company's ability to develop and protect its technologies; the Company's ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company's stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of the Company's Form 10-K filed with the SEC on March 31, 2025, and other documents filed by the Company from time to time with the SEC.
Fast Company
36 minutes ago
- Fast Company
These are the top 10 emerging technologies of 2025, according to the World Economic Forum
Breakthroughs happen all the time in the tech world, but only a select few manage to make a lasting impact. Predicting which innovations will shape the future is always a challenge. On Tuesday, the World Economic Forum (WEF) released its list of the top 10 emerging technologies of 2025, highlighting those expected to influence global challenges within the next three to five years. The list, compiled with the help of Frontiers Media, a publisher of peer-reviewed scientific journals, avoids naming specific companies. Instead, the WEF focuses on concepts that are both novel and nearing maturity, with the potential to deliver meaningful benefits to society. Here's what the WEF sees as being on the path to a breakthrough in 2025. Advanced nuclear tech Demand for nuclear energy is on the rise, with the Trump administration pledging to fast-track permits for nuclear projects. The WEF predicts that smaller nuclear designs and alternative cooling systems will offer safer, cleaner energy at a lower cost. These reactors, it says, 'could play a key role in building reliable, zero-carbon power systems.' Structural battery composites The weight of batteries has been a pain point for things like cars and planes, impacting their efficiency. New materials that store energy and support weight can make these vehicles lighter, improving both their performance and their environmental impact. Collaborative sensing Speaking of vehicles, networking connected sensors can let vehicles share information in real time with each other, as well as with cities and emergency services. In the case of an incident, this can reduce traffic, increase response times, and improve safety, the WEF says. Generative watermarking As artificial intelligence becomes even more widespread, distinguishing original content from AI-generated material will be critical. Generative watermarking adds an invisible tag to AI content, helping combat misinformation and build consumer trust. Green nitrogen Producing fertilizer today requires fossil fuels, which leads to pollution and carbon emissions. Green nitrogen, which relies on electricity instead, could offer 'a more sustainable way to grow food,' the WEF says. GLP-1 drugs for neurodegenerative diseases GLP-1 drugs are currently used to treat obesity and diabetes. The WEF notes they are also showing promise in treating other diseases, such as Alzheimer's and Parkinson's. Autonomous biochemical sensing Smart sensors capable of continuously monitoring environmental changes or human health without wires could unlock numerous possibilities. The medical field may use them for early disease detection, while scientists can apply them to track pollution and atmospheric trends. Nanozymes Naturally occurring enzymes help clean pollution and are used in medical diagnostics. Lab-made versions, called nanozymes, are stronger and cheaper, which could expand their use in a variety of applications. Engineered living therapeutics Long-term medical care is expensive and often inconsistent in its results. Scientists, according to the WEF, are developing therapies that use beneficial bacteria to deliver treatments from within the body. This approach could lower costs and improve success rates. Osmotic power systems This renewable energy source, which uses the pressure difference that occurs when freshwater and saltwater mix, produces a cleaner form of electricity. That can be especially helpful in coastal areas where special care must be taken to protect both the environment and wildlife.
